Tocagen and ApolloBio Enter License Agreement to Develop and Commercialize Toca 511 & Toca FC in the Greater China Region

Author's Avatar
Apr 19, 2018
Article's Main Image

Tocagen eligible to receive up to $127 million in upfront payment, development and commercial milestones, plus additional double-digit tiered sales royalties

Upfront and near-term development milestones payments total up to $20 million

PR Newswire